Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1238227.RACZR-xb0vEe2DA5JS5Dd76RvFt7A-Jlrjb9Mpy-Dri2E130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1238227.RACZR-xb0vEe2DA5JS5Dd76RvFt7A-Jlrjb9Mpy-Dri2E130_assertion type Assertion NP1238227.RACZR-xb0vEe2DA5JS5Dd76RvFt7A-Jlrjb9Mpy-Dri2E130_head.
- NP1238227.RACZR-xb0vEe2DA5JS5Dd76RvFt7A-Jlrjb9Mpy-Dri2E130_assertion description "[The present study demonstrated that Rab25 mediated the sensitivity of ovarian cancer to cisplatin, a first?line chemotherapeutic agent for the treatment of ovarian cancer in the clinic.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1238227.RACZR-xb0vEe2DA5JS5Dd76RvFt7A-Jlrjb9Mpy-Dri2E130_provenance.
- NP1238227.RACZR-xb0vEe2DA5JS5Dd76RvFt7A-Jlrjb9Mpy-Dri2E130_assertion evidence source_evidence_literature NP1238227.RACZR-xb0vEe2DA5JS5Dd76RvFt7A-Jlrjb9Mpy-Dri2E130_provenance.
- NP1238227.RACZR-xb0vEe2DA5JS5Dd76RvFt7A-Jlrjb9Mpy-Dri2E130_assertion SIO_000772 25405658 NP1238227.RACZR-xb0vEe2DA5JS5Dd76RvFt7A-Jlrjb9Mpy-Dri2E130_provenance.
- NP1238227.RACZR-xb0vEe2DA5JS5Dd76RvFt7A-Jlrjb9Mpy-Dri2E130_assertion wasDerivedFrom befree-2016 NP1238227.RACZR-xb0vEe2DA5JS5Dd76RvFt7A-Jlrjb9Mpy-Dri2E130_provenance.
- NP1238227.RACZR-xb0vEe2DA5JS5Dd76RvFt7A-Jlrjb9Mpy-Dri2E130_assertion wasGeneratedBy ECO_0000203 NP1238227.RACZR-xb0vEe2DA5JS5Dd76RvFt7A-Jlrjb9Mpy-Dri2E130_provenance.